Platform Device

MicroTransponder is developing a platform technology for wireless neurostimulation. The first product being developed is the SAINT™ (Subcutaneous Array of Implantable Neural Transponders) System*. The SAINT™ eliminates the need for an implantable battery or wires. It is implantable in a simple 30 minute outpatient procedure. This implanted platform technology will be powered and controlled by an external controller, which will be similar in form and function to a smartphone. The patient will be able to adjust the stimulus parameters according to the level of pain he or she is experiencing.

 *Investigational Device, Not for Sale in the United States, limited by Federal law.

Current Treatments for Chronic Pain

Each year over 40 million Americans suffer from chronic pain. They miss over 500 million days of work, and spend billions on doctor visits and treatment. Current pharmaceutical treatment options often have negative side effects. Many become ineffective over time for large percentages of the patient population. Over $2.5 Billion is spent annually on neurostimulation treatments in the U.S., but out of the 70,000 annual trial implantations, only 50% of the patients elect to get a permanent implant. Of those 35,000; 50% fail in the first year and 70% by the third year. Only 1 in 7 devices implanted is a long term success. Most of these failures are a result of wire breakage or migration. The SAINT™ has been designed with these issues in mind to provide a long term solution for chronic pain.